Data Collection Flashcards
How many patients was in the Cefdinir project
230 patients were included in the final study analysis with 113 in the cefdinir group and 117 in the other oral cephalosporin
group
Cefdinir primary outcome
Evaluate rates UTI recurrence with the same organism within 30 days of completing IV antibiotics followed by cefdinir
Cefdinir secondary outcome
Recurrent UTI with any organism within 30 days
Cefdinir result
This study found no difference in incidence of UTI recurrence after treatment with cefdinir compared to other oral cephalosporins.
Standard enoxaparin VTE
prophylaxis
40 mg SQ daily
Standard heparin VTE
prophylaxis
5000 units SQ q8h
Intermediate enoxaparin VTE prophylaxis
0.5 mg/kg SQ twice daily
Intermediate heparin VTE prophylaxis
7500 units SQ q8h
enoxaparin VTE treatment
1 mg/kg SQ twice daily
heparin VTE treatment
drip
when to use Standard VTE
prophylaxis
D-dimer < 3 mcg/mL
when to use Intermediate VTE
prophylaxis
D-dimer >3 mcg/mL
or ICU admission
Devyn primary outcome
Incidence of thromboembolism when Mount Carmel COVID Treatment Guideline is appropriately utilized to initiate anticoagulation
Incidence of thromboembolism with standard, intermediate, and therapeutic anticoagulation
Devyn results
There were no statistically significant differences in dosing intensity of anticoagulants for
prevention of VTE formation when comparing standard, intermediate, and therapeutic dosing
regimens.
How many patient in devyn’s project
482 patients were included in this study. Enoxaparin was prescribed on admission for 290 patients, heparin was prescribed for 127 patients, and a DOAC was prescribed for 65
patients.
HF primary outcome
rate of GDMT
optimization based on various factors.
HF number of patients
442 patients met criteria for this study.
HF results
284 (64.25%) received some form of GDMT optimization, the majority of which 246 (55.7%) had at least one GDMT drug added.
Patients with cardiology consult were more likely to have GDMT optimization while increased serum creatinine (SCr) and age were associated with a lower chance of GDMT optimization
Dificid primary outcome
assess physician adherence to current MCHS fidaxomicin restrictions for CDI, which limit its use to patients with vancomycin failure or those continuing home therapy
Dificid secondary outcome
examining proposed updated fidaxomicin restrictions, which allowed its use for patients with recurrent CDI or those at high risk for recurrence/severe CDI
Dificid result
35% (17/48) of fidaxomicin patients met the current fidaxomicin restrictions. 92% (44/48) of fidaxomicin treated patients met the proposed restrictions including risk for recurrence.
OSU primary outcome
impact of a pharmacy resident antimicrobial stewardship overnight on-call program on clinical outcomes in patients with bloodstream infections (BSI) secondary to multidrug-resistant organisms
OSU result
The primary outcome of time from RDT result to first dose administration of optimal antibiotic therapy was a median of 3.3 hours in the PI group versus 2.3 hours in the AI group (p= 0.057). In-hospital mortality, length of stay, and BSI recurrence were similar between groups.
